🚀 VC round data is live in beta, check it out!
Bio-Rad Laboratories Overview
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Founded
1975
HQ
Employees
7.5K
Website
Financials (LTM)
EV
$8B
Bio-Rad Laboratories Financials
Bio-Rad Laboratories reported last 12-month revenue of $3B and EBITDA of $460M.
In the same LTM period, Bio-Rad Laboratories generated $1B in gross profit, $460M in EBITDA, and $272M in net income.
Revenue (LTM)
Bio-Rad Laboratories P&L
In the most recent fiscal year, Bio-Rad Laboratories reported revenue of $3B and EBITDA of $1B.
Bio-Rad Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $460M | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 47% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $272M | XXX | $760M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 29% | XXX | XXX | XXX |
| Net Debt | — | — | $675M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bio-Rad Laboratories Stock Performance
Bio-Rad Laboratories has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
Bio-Rad Laboratories' stock price is $295.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | 0.0% | XXX | XXX | XXX | $28.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBio-Rad Laboratories Valuation Multiples
Bio-Rad Laboratories trades at 3.0x EV/Revenue multiple, and 17.0x EV/EBITDA.
EV / Revenue (LTM)
Bio-Rad Laboratories Financial Valuation Multiples
As of April 19, 2026, Bio-Rad Laboratories has market cap of $8B and EV of $8B.
Equity research analysts estimate Bio-Rad Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bio-Rad Laboratories has a P/E ratio of 29.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 17.0x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBIT | 24.9x | XXX | 25.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | 5.8x | XXX | XXX | XXX |
| P/E | 29.2x | XXX | 10.5x | XXX | XXX | XXX |
| EV/FCF | 20.6x | XXX | 20.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bio-Rad Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bio-Rad Laboratories Margins & Growth Rates
Bio-Rad Laboratories' revenue in the last 12 month grew by 2%.
Bio-Rad Laboratories' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Bio-Rad Laboratories' rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bio-Rad Laboratories' rule of X is 22% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bio-Rad Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | (62%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bio-Rad Laboratories Public Comps
See public comps and valuation multiples for other Medical Devices comps.
Valuation data powered by FactSet, Inc.
Bio-Rad Laboratories M&A Activity
Bio-Rad Laboratories acquired XXX companies to date.
Last acquisition by Bio-Rad Laboratories was on XXXXXXXX, XXXXX. Bio-Rad Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bio-Rad Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBio-Rad Laboratories Investment Activity
Bio-Rad Laboratories invested in XXX companies to date.
Bio-Rad Laboratories made its latest investment on XXXXXXXX, XXXXX. Bio-Rad Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bio-Rad Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bio-Rad Laboratories
| When was Bio-Rad Laboratories founded? | Bio-Rad Laboratories was founded in 1975. |
| Where is Bio-Rad Laboratories headquartered? | Bio-Rad Laboratories is headquartered in United States. |
| How many employees does Bio-Rad Laboratories have? | As of today, Bio-Rad Laboratories has over 7K employees. |
| Who is the CEO of Bio-Rad Laboratories? | Bio-Rad Laboratories' CEO is Norman Schwartz. |
| Is Bio-Rad Laboratories publicly listed? | Yes, Bio-Rad Laboratories is a public company listed on NYSE. |
| What is the stock symbol of Bio-Rad Laboratories? | Bio-Rad Laboratories trades under BIO ticker. |
| When did Bio-Rad Laboratories go public? | Bio-Rad Laboratories went public in 1980. |
| Who are competitors of Bio-Rad Laboratories? | Bio-Rad Laboratories main competitors are Cochlear, Demant, Glaukos, Shimadzu. |
| What is the current market cap of Bio-Rad Laboratories? | Bio-Rad Laboratories' current market cap is $8B. |
| What is the current revenue of Bio-Rad Laboratories? | Bio-Rad Laboratories' last 12 months revenue is $3B. |
| What is the current revenue growth of Bio-Rad Laboratories? | Bio-Rad Laboratories revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Bio-Rad Laboratories? | Current revenue multiple of Bio-Rad Laboratories is 3.0x. |
| Is Bio-Rad Laboratories profitable? | Yes, Bio-Rad Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bio-Rad Laboratories? | Bio-Rad Laboratories' last 12 months EBITDA is $460M. |
| What is Bio-Rad Laboratories' EBITDA margin? | Bio-Rad Laboratories' last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Bio-Rad Laboratories? | Current EBITDA multiple of Bio-Rad Laboratories is 17.0x. |
| What is the current FCF of Bio-Rad Laboratories? | Bio-Rad Laboratories' last 12 months FCF is $378M. |
| What is Bio-Rad Laboratories' FCF margin? | Bio-Rad Laboratories' last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Bio-Rad Laboratories? | Current FCF multiple of Bio-Rad Laboratories is 20.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.